Matches in Wikidata for { <http://www.wikidata.org/entity/Q65342427> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- Q65342427 description "clinical trial" @default.
- Q65342427 description "ensayu clínicu" @default.
- Q65342427 description "klinisch onderzoek" @default.
- Q65342427 description "клінічне випробування" @default.
- Q65342427 name "Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors" @default.
- Q65342427 name "Phase 1b/2 Trial of Lenvatinib" @default.
- Q65342427 type Item @default.
- Q65342427 label "Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors" @default.
- Q65342427 label "Phase 1b/2 Trial of Lenvatinib" @default.
- Q65342427 prefLabel "Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors" @default.
- Q65342427 prefLabel "Phase 1b/2 Trial of Lenvatinib" @default.
- Q65342427 P1132 Q65342427-AC258926-BEAE-4B65-B9F4-BAE328EC450E @default.
- Q65342427 P1476 Q65342427-3A19BA82-1B9C-407B-9425-77C8EE266EF1 @default.
- Q65342427 P17 Q65342427-0DC20891-A9A8-4511-B3F3-1997F6FFA728 @default.
- Q65342427 P17 Q65342427-5180A6B6-9DB3-429D-8BE7-19D3DECD183A @default.
- Q65342427 P17 Q65342427-DAD689F9-89DE-4ACB-98B1-C3F664D5BA4F @default.
- Q65342427 P2899 Q65342427-4F0E9FA2-4514-4595-BE28-28CA19BEAE0C @default.
- Q65342427 P3098 Q65342427-2A634C9A-0B68-4E32-816E-884DF48C9F3B @default.
- Q65342427 P31 Q65342427-A59A5351-88F2-48A2-B515-73A9B3B72372 @default.
- Q65342427 P4844 Q65342427-FA7C9152-7D1A-4754-9490-329B24213B38 @default.
- Q65342427 P580 Q65342427-4EE2BF45-7964-46E0-B378-D9E781ED004F @default.
- Q65342427 P582 Q65342427-8BE66D3E-549B-49F4-8C92-77D43D299549 @default.
- Q65342427 P6099 Q65342427-095774A0-9980-4D85-9462-8A5DA62D8AF0 @default.
- Q65342427 P6099 Q65342427-C1D14575-B008-43F7-8FDA-75B89AC3A3FC @default.
- Q65342427 P6153 Q65342427-0DC29D14-EA2D-4053-9A4A-A9004528FA7B @default.
- Q65342427 P6153 Q65342427-3260ED42-70AB-4BA6-A589-2324F20C19E2 @default.
- Q65342427 P6153 Q65342427-45B113A4-EE62-4860-82B5-32307C7536DB @default.
- Q65342427 P6153 Q65342427-494C2A02-B710-403C-A0EB-9E3A70EDEB33 @default.
- Q65342427 P6153 Q65342427-5BAD251C-37D7-4A0F-A5B8-A16135669C07 @default.
- Q65342427 P6153 Q65342427-80CED11D-FF41-4FE1-8667-81706110BC98 @default.
- Q65342427 P6153 Q65342427-9AE4E164-D491-4391-9A1D-8C19D4DB1252 @default.
- Q65342427 P6153 Q65342427-B1424296-E1B5-4487-906F-C84978A82AE9 @default.
- Q65342427 P6153 Q65342427-C2BB5532-23C0-4E5C-B111-97B719599A68 @default.
- Q65342427 P6153 Q65342427-ECBD99CF-7D39-44BE-8118-DC8D34CDBE1F @default.
- Q65342427 P6153 Q65342427-F63BBABC-413B-4DBA-A48F-11ACB43C140B @default.
- Q65342427 P8363 Q65342427-62746CA5-D10D-4A5D-98B9-C2E8A8EF08F4 @default.
- Q65342427 P1132 "+329" @default.
- Q65342427 P1476 "A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors" @default.
- Q65342427 P17 Q20 @default.
- Q65342427 P17 Q29 @default.
- Q65342427 P17 Q30 @default.
- Q65342427 P2899 "+18" @default.
- Q65342427 P3098 "NCT02501096" @default.
- Q65342427 P31 Q30612 @default.
- Q65342427 P4844 Q13896859 @default.
- Q65342427 P580 "2015-07-22T00:00:00Z" @default.
- Q65342427 P582 "2020-02-29T00:00:00Z" @default.
- Q65342427 P6099 Q42824440 @default.
- Q65342427 P6099 Q5452194 @default.
- Q65342427 P6153 Q1808012 @default.
- Q65342427 P6153 Q282097 @default.
- Q65342427 P6153 Q30253911 @default.
- Q65342427 P6153 Q30254321 @default.
- Q65342427 P6153 Q30270311 @default.
- Q65342427 P6153 Q30280839 @default.
- Q65342427 P6153 Q30293330 @default.
- Q65342427 P6153 Q4700653 @default.
- Q65342427 P6153 Q4897536 @default.
- Q65342427 P6153 Q49117 @default.
- Q65342427 P6153 Q812573 @default.
- Q65342427 P8363 Q78089383 @default.